Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHROMA: Lampalizumab for Geographic Atrophy
NCT02247479Phase 3Terminated
- Sponsor
- Roche
- Start
- Sep 2014
- Primary completion
- Jan 2018
- Modality
- Antibody Fragments
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of lampalizumab in geographic atrophy (GA) (3 arms), sponsored by Roche. Primary endpoints: Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at 48 weeks and Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at 48 weeks. Started Sep 2014; status: terminated.
02
Drugs
lampalizumab
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02247479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02247479.